Metropolitan Life Insurance Company (MetLife)’s Generation Bio GBIO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-251	Closed	-$10.2K	–	830
2024 Q1	$10.2K	Buy	+251	New	+$5.91K	﹤0.01%	2126
2023 Q4	–	Sell	-266	Closed	-$10.1K	–	2363
2023 Q3	$10.1K	Hold	266	–	–	﹤0.01%	2204
2023 Q2	$14.6K	Buy	+266	New	+$12.2K	﹤0.01%	2099
2023 Q1	–	Sell	-307	Closed	-$12.1K	–	2368
2022 Q4	$12.1K	Buy	307 +213	+227%	+$11.2K	﹤0.01%	2223
2022 Q3	$4.97K	Sell	94 -211	-69%	-$13.2K	﹤0.01%	2302
2022 Q2	$20K	Hold	305	–	–	﹤0.01%	2054
2022 Q1	$22.4K	Sell	305 -708	-70%	-$41K	﹤0.01%	2035
2021 Q4	$71.7K	Sell	1,013 -185	-15%	-$32.3K	﹤0.01%	2629
2021 Q3	$300K	Hold	1,198	–	–	﹤0.01%	1765
2021 Q2	$322K	Buy	1,198 +57	+5%	+$17.1K	﹤0.01%	2291
2021 Q1	$325K	Buy	1,141 +756	+196%	+$242K	﹤0.01%	1697
2020 Q4	$109K	Hold	385	–	–	﹤0.01%	2315
2020 Q3	$119K	Buy	+385	New	+$92.1K	﹤0.01%	2116

Other funds holding GBIO

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s GBIO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Generation Bio (GBIO) in Q2 2024, closing a stake of 251 shares — an estimated $10.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in GBIO in Q3 2020 and held it in 13 quarters. The position peaked at $325K in Q1 2021. 77 funds tracked by Wall St. Rank hold GBIO as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Generation Bio position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 251 Generation Bio shares in Q2 2024, an estimated $10.2K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Generation Bio in Q3 2020 and held it in 13 quarters.
Metropolitan Life Insurance Company (MetLife)'s Generation Bio position peaked at $325K in Q1 2021.
77 funds tracked by Wall St. Rank held Generation Bio as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.